Skip to content

To study the efficacy of Virechana (purgation therapy) of Ayurveda in changes in gut microbiota (intestinal bacterial modulation) in healthy individuals

â??Study the physiological basis and gut bacterial modulations induced by Virechana (Purgation therapy) in Healthy adults: A prospective longitudinal studyâ??

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033639
Enrollment
80
Registered
2021-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Virechana with Trivrit levy 50gms orally on last day of virecana once. Guduchi ghoorna 3 gms bid orally for 3 to 5 days till deepen pachana laxanas observed, Cow ghee (goghrita) up to 2

Sponsors

Central Council of Research in Ayurvedic Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Healthy female subjects and/or male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy individual are screened based on the proforma (CRF) of Ayurvedic parameters of health as well as detailed medical history for identifying no clinically relevant abnormalities, full physical examination, including BP and pulse rate measurement, 12-lead ECG, or clinical laboratory tests. 2. Body mass index (BMI) 3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. 4. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion criteria: Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic (including alcoholic liver disease, non-alcoholic steatohepatitis (NASH), autoimmune hepatitis, and hereditary liver diseases), psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing). 2. Evidence or history of clinically significant dermatological condition (e.g. contact dermatitis or psoriasis) or visible rash present during physical examination. 3. History of regular alcohol consumption within 6 months before screening. 4. Participation in any clinical trial in the last 3 months which if the investigator seems prudent to be considered an exclusion criteria and many other (due to words limit all exclusion criteria not added)

Design outcomes

Primary

MeasureTime frame
Prim: Changes in the gut microbial profile.Timepoint: 18 days to 26 days of intervention with follow up of 3 months

Secondary

MeasureTime frame
1. Change in the body composition (muscle mass, fat mass). 2. Changes in the resting metabolic rate (RMR). 3. Changes in the lipid profile, complete blood count, serum insulin, blood sugar levels, thyroid profile, liver function tests, kidney function tests, ghrelin, leptin, IgE, Vit B12, Vit D, IFN-gamma,TNF-α, IL-1β, glutathione levels, complement protein C3-C4. 4. Changes in the Oja assessment BODE index, SF36 and pain and fatigue score. 5. Change in Agni assessment ScaleTimepoint: 18 days to 26 days of intervention with follow up of 3 months

Countries

India

Contacts

Public ContactVittal Huddar

All India Institute of Ayurveda

dr.vghuddar@aiia.gov.in011-26950401

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026